Our findings emphasize the critical role of SMARCA4 immunohistochemical analysis in accurately identifying SD-LCNEC, particularly in cases with low neuroendocrine marker and TTF-1 expression. This evidence concerns the gene TTF1 and large cell neuroendocrine carcinoma.